非布司他治疗慢性痛风性关节炎的疗效及对核苷酸结合寡聚化结构域样受体3炎性体的影响  

Efficacy of Febuxostat in Treatment of Chronic Gouty Arthritis and its Effects on NALP3 Inflammasome

作　　者：杨显华[1] 李名波[2] 李青霞 YANG Xianhua;LI Mingbo;LI Qingxia(Dept.of Clinical;Dept.of Nephrology and China;Dept.of Pharmnacy,Lab,Qianjiang Central Hospital,Rheumatology,Qianjiang Central Qianjiang Central Hospital,Hubei Qianjiang 433100,China)

机构地区：[1]潜江市中心医院检验科,湖北潜江433100 [2]潜江市中心医院肾病风湿科,湖北潜江433100 [3]潜江市中心医院药剂科,湖北潜江433100

出　　处：《中国医院用药评价与分析》2018年第10期1367-1369,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:探讨非布司他治疗慢性痛风性关节炎的疗效及对核苷酸结合寡聚化结构域样受体3(NALP3)炎性体的影响。方法:选取2015年7月至2017年3月潜江市中心医院收治的慢性痛风性关节炎患者76例,采用随机数字表法分为观察组和对照组,每组38例。对照组患者给予别嘌醇治疗,观察组患者给予非布司他治疗。观察两组患者的尿酸(UA)、NALP3炎性体水平,目标UA水平达标情况及临床疗效。结果:治疗后,观察组患者UA、NALP3炎性体水平明显低于对照组,差异有统计学意义(P<0.05);观察组患者目标UA水平达标率为60.53%(23/38),明显高于对照组的42.11%(16/38),差异有统计学意义(P<0.05)。观察组患者的总有效率为92.11%(35/38),明显高于对照组的78.95%(30/38),差异有统计学意义(P<0.05)。结论:非布司他治疗慢性痛风性关节炎的疗效显著,可降低患者UA、NALP3炎性体水平,改善患者急性期发作症状。OBJECTIVE： To probe into the efficacy of febuxostat in treatment of chronic gouty arthritis and its effects on NALP3 inflammasome. METHODS： 76 patients with chronic gouty arthritis admitted into Qianjiang Central Hospital from Jul. 2015 to Mar. 2017 were selected and divided into observation group and control group via random number table, with 38 cases in each group. The control group was treated with allopurinol, while the observation group was given febuxostat. The uric acid（UA） level, NALP3 inflammasome level, compliance rates of target UA level and clinical efficacy of two groups were observed. RESULTS： After treatment, the UA and NALP3 inflammasome levels of observation group were significantly lower than those of the control group, with statistically significant differences（P0.05）. After treatment, the compliance rate of target UA level was 60.53%（23/38）, which was significantly higher than that of the control group（42.11%, 16/38）, with statistically significant difference（P0.05）. The total effective rate of observation group was 92.11%（35/38）, which was significantly higher than that of the control group（78.95%, 30/38）, with statistically significant difference（P0.05）. CONCLUSIONS： The efficacy of febuxostat in treatment of chronic gouty arthritis is remarkable, which can lower the UA and NALP3 inflammasome levels, improve symptoms of acute phase attacks.

关 键 词：非布司他 别嘌呤 痛风性关节炎 

分 类 号：R979.5[医药卫生—药品]